摘要
由于手术、放化疗等手段的治疗效果有限,免疫治疗的出现为膀胱癌治疗带来了新希望。程序性死亡受体1(PD-1)/PD-1配体(PD-L1)抑制剂作为免疫检查点抑制剂,在晚期膀胱癌的治疗中显示出了良好的抗肿瘤活性,且安全性良好,已被NCCN指南推荐用于晚期膀胱癌的二线治疗。PD-1/PD-L1抑制剂已经覆盖了晚期膀胱癌一线或二线治疗、一线化疗后维持治疗,肌层浸润性膀胱癌的辅助、新辅助治疗,卡介苗灌注失败的高危非肌层浸润性膀胱癌的治疗及肌层浸润性膀胱癌保膀胱治疗等,相关研究或已取得了一定的效果,或正在进行中,尚有待进一步深入研究,有望为临床上膀胱癌的治疗提供新的思路。
Because of the limited effect of traditional treatment methods such as surgical treatment,radiotherapy and chemotherapy,the emergence of immunotherapy has brought new hope for the treatment of patients with bladder cancer.As an immune checkpoint inhibitor,programmed death receptor 1/programmed death receptor-ligand 1(PD-1/PD-L1)inhibitor has shown good anti-tumor activity and safety in the treatment of advanced bladder cancer,and has been recommended for advanced bladder cancer as second-line treatment by NCCN guidelines.PD-1/PD-L1 inhibitor for the treatment of bladder cancer has covered the first-line and second-line treatment,as well as maintenance therapy after first-line chemotherapy of locally advanced or metastatic bladder cancer,adjuvant and neoadjuvant therapy of muscle-invasive bladder cancer,treatment of high-risk non-muscle invasive bladder cancer failed by Bacille Calmette-Guérin vaccine perfusion,and bladder preservation therapy of muscle-invasive bladder cancer.Some of related studies have achieved certain results,and some are in progress,both of which need to be further examined.Maybe it can provide new guidance and ideas for clinical treatment of bladder cancer.
作者
张凡
李彦佑
史正奇
王城博
董治龙
Zhang Fan;Li Yanyou;Shi Zhengqi;Wang Chengbo;Dong Zhilong(Department of Urology,Lanzhou University Sencond Hospital,Key Laboratory of Gansu Province for Urological Diseases,Gansu Nephro-Urological Clinical Center,Lanzhou 730030,China)
出处
《中华外科杂志》
CAS
CSCD
北大核心
2021年第11期952-955,共4页
Chinese Journal of Surgery
